Pyronaridine
Подписчиков: 0, рейтинг: 0
| Clinical data | |
|---|---|
| Other names | Pyronaridine tetraphosphate |
| Routes of administration |
Oral, intramuscular injection, intravenous therapy |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C29H32ClN5O2 |
| Molar mass | 518.06 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
|
| |
Pyronaridine is an antimalarial drug. It was first made in 1970 and has been in clinical use in China since the 1980s.
In a small (n=88) malaria study in Camaroon, pyronaridine had a 100% cure rate, compared with 60% for chloroquine.
It is one of the components of the artemisinin combination therapy pyronaridine/artesunate (Pyramax).
It has also been studied as a potential anticancer drug, and treatment for Ebola. The combination of pyronaridine and artesunate has been evaluated to have a synergistic effect of stronger antiviral effect and less toxicity. The combination of pyronaridine and artesunate is being studied as a possible treatment for moderate to severe SARS-COV-2.
| Alveo- late |
|
||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hetero- kont |
|||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||